Akhil Santhosh, Medical Oncology Specialist at MVR Cancer Centre and Research Institute, shared a post on LinkedIn:
“Checkmate 9DW may have set an unprecedented benchmark in terms of overall survival in advanced HCC, but the trial comes with its own caveats and nuances. Here in this edition of Lancet, we raised few pressing issues pertaining to the trial and why this regimen should not yet be the 1st go to option for practising oncologists worldwide.”
Nihanthy Sreenath, Consultant of Medical Oncology and Hemato-Oncology at Saroj Gupta Cancer Centre and Research Institute, shared Akhil Santhosh‘s post, adding:
“CheckMate 9DW sets an impressive survival benchmark in advanced HCC, but its real-world applicability is far more nuanced. In our Lancet commentary, we outline key considerations that clinicians should consider before adopting this regimen as the universal first-line standard. Context, patient selection, and practical feasibility remain important considerations.
Grateful to contribute to this important conversation Akhil Santhosh.”
Title: Treatments for unresectable hepatocellular carcinoma: insights from CheckMate 9DW
Authots: Akhil Santhosh, Nihanthy D Sreenath
Read the Full Article on The Lancet
You can also read: FDA Approves Nivolumab and Ipilimumab for First-Line Treatment of Unresectable Hepatocellular Carcinoma Based on CheckMate-9DW Trial
